By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – XDx today said that Highmark, a health insurer that covers around 4.8 million lives in Pennsylvania and West Virginia, is now covering its AlloMap test for beneficiaries of the health plan.

The AlloMap test is a gene expression-based assay used to aid the monitoring of heart transplant rejection. The test measures the expression levels of 20 genes from a blood sample to provide a score that is used by clinicians to help evaluate the risk of transplant rejection.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

NPR reports that Turkish high school students will no longer study evolution.

Researchers report they sequenced and identified plant species in an "al fresco" laboratory.

An Australian team searches for genetic alterations linked to depression in hopes of developing personalized treatments, the Sydney Morning Herald reports.

In PNAS this week: host contributors to typhoid fever risk, effects of obesity-related variants near TMEM18, and more.